Clinical Trial Update: Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating topotecan for recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-06-26